Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

NCT02525939 is registered in ClinicalTrials.gov with DalCor Pharmaceuticals as lead sponsor.

NCT NCT02525939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02525939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Lead sponsor
DalCor Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2016
Completion date
October 31, 2021
Enrollment
6,147 (actual)
Sites
557

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome